A Randomised, Cross-over Study to Evaluate Efficacy and Tolerability of FLX-787 in Patients with Motor Neuron Disease
Phase of Trial: Phase I
Latest Information Update: 31 Jan 2017
At a glance
- Drugs FLX 787 (Primary)
- Indications Amyotrophic lateral sclerosis
- Focus Therapeutic Use
- Acronyms Flex-202
- Sponsors Flex Pharma
- 30 Jan 2017 Status changed from not yet recruiting to recruiting.
- 23 Aug 2016 Planned End Date changed from 30 Dec 2016 to 31 May 2017.
- 13 Aug 2016 New trial record